VolitionRx Stock Forecast for 2023 - 2025 - 2030
Updated on 04/30/2024
VolitionRx Stock Forecast and Price Target
In recent months, notable analysts have provided yearlong price targets for VolitionRx, with the average target coming in at $3.95. If it were to be achieved, this would result in a potential upside of approximately 359.3 percent from the most recent closing price in April, 2024. The high end is $4.50, and the low is $2.50. If you're looking for information on VolitionRx stock, consider checking out the forecasts for comparable firms such as NasdaqGS:IDXX.
359.30% Upside
VolitionRx Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, VolitionRx's Price has grown, increasing from $0.00 to $0.00 – a growth of 100.00%. The next year looks promising for VolitionRx, with analysts predicting Fair Value of $0.92 – an increase of 100.00%. Over the next seven years, experts anticipate that VolitionRx's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IDXX Stock Forecast | IDEXX Laboratories | Outperform |
14
|
$505.34 | Buy/Sell | $583.92 | 18.73% |
| TXG Stock Forecast | 10x Genomics | Outperform |
6
|
$28.40 | Buy/Sell | $58.14 | 83.10% |
| LNTH Stock Forecast | Lantheus Holdings | Buy |
14
|
$67.26 | Buy/Sell | $91.75 | 45.70% |
| QDEL Stock Forecast | Quidel Corp | Hold |
16
|
$39.36 | Buy/Sell | $121.00 | 35.16% |
| IMMU Stock Forecast | Immunomedics | - |
2
|
$0.48 | Buy/Sell | $47.60 | -100.00% |
VolitionRx Revenue Forecast for 2023 - 2025 - 2030
In the last two years, VolitionRx's Revenue has grown, increasing from $10000.00 to $90.00k – a growth of 800.00%. The next year looks promising for VolitionRx, with analysts predicting Revenue of $7.58M – an increase of 8322.22%. Over the next seven years, experts anticipate that VolitionRx's Revenue will grow at a rate of 305344.44%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GH Stock Forecast | Guardant Health | Buy |
6
|
$18.19 | Buy/Sell | $43.00 | 141.89% |
| LMNX Stock Forecast | Luminex | - |
12
|
$36.99 | Buy/Sell | $37.00 | -100.00% |
| MYGN Stock Forecast | Myriad Genetics | Hold |
6
|
$19.80 | Buy/Sell | $22.08 | 26.26% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VCYT Stock Forecast | Veracyte | Outperform |
11
|
$20.34 | Buy/Sell | $32.17 | 59.78% |
| VIVO Stock Forecast | Meridian Bioscience | - |
18
|
$0.03 | Buy/Sell | $34.00 | -100.00% |
| HSKA Stock Forecast | Heska | - |
12
|
$119.99 | Buy/Sell | $125.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LXRX Stock Forecast | Lexicon Pharmaceuticals | Outperform |
6
|
$1.56 | Buy/Sell | $5.15 | 156.41% |
| ADPT Stock Forecast | Adaptive Biotechnologies | Outperform |
6
|
$2.75 | Buy/Sell | $8.67 | 118.18% |
| CELC Stock Forecast | Celcuity | Buy |
9
|
$16.05 | Buy/Sell | $23.33 | 68.22% |
VolitionRx EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, VolitionRx's EBITDA has grown by 24.99%, rising from $-20.53M to $-25.66M. For next year, analysts predict EBITDA of $-32.10M, which would mean an increase of 25.10%. Over the next seven years, experts predict that VolitionRx's EBITDA will grow at a rate of 1082.39%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| OSUR Stock Forecast | OraSure Technologies | Hold |
11
|
$5.40 | Buy/Sell | $7.40 | 34.26% |
| CDNA Stock Forecast | CareDx, Inc | Outperform |
9
|
$8.20 | Buy/Sell | $11.80 | 52.44% |
| CDMO Stock Forecast | Avid Bioservices | Outperform |
12
|
$7.56 | Buy/Sell | $18.50 | 85.19% |
VolitionRx EBIT Forecast for 2023 - 2025 - 2030
In the last two years, VolitionRx's EBIT has grown by 49.55%, rising from $-21.25M to $-31.78M. For next year, analysts predict EBIT of $-37.65M, which would mean an increase of 18.47%. In 2030, professionals predict that VolitionRx's EBIT will decrease by 543.58%, to $140.97M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A950130 Stock Forecast | Access Bio | - |
7
|
₩6.41k | Buy/Sell | ₩8.40k | -100.00% |
| PSNL Stock Forecast | Personalis | Outperform |
6
|
$1.36 | Buy/Sell | $4.45 | 194.12% |
| AWH Stock Forecast | Aspira Women's Health | Hold |
7
|
$3.33 | Buy/Sell | $4.80 | -0.90% |
VolitionRx EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, VolitionRx's EPS has grown, increasing from $-0.46 to $0.00 – a growth of 100.00%. The next year looks promising for VolitionRx, with analysts predicting EPS of $-0.44 – an increase of 100.00%. Over the next seven years, experts anticipate that VolitionRx's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MYMD Stock Forecast | Akers Biosciences | - |
0
|
$4.24 | Buy/Sell | $0.00 | -100.00% |
| LUDG Stock Forecast | Ludwig Enterprises | - |
0
|
$0.26 | Buy/Sell | $0.00 | -100.00% |
| ICCC Stock Forecast | ImmuCell | - |
0
|
$5.10 | Buy/Sell | $14.00 | -100.00% |
.jpg)